# NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Advances

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability.” The feature highlights how breakthroughs in nanocarrier-based delivery are reshaping cancer therapy by enhancing efficacy and reducing toxicity. Oncotelic’s proprietary Deciparticle(TM) platform is spotlighted for its potential to improve the bioavailability and therapeutic index of oncology drugs, advancing the broader shift toward precision nanomedicine.

 To view the full press release, visit https://nnw.fm/F5U3f

 About Oncotelic Therapeutics Inc.

 Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

 NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC

 About NetworkNewsWire

 NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

 To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.NetworkNewsWire.com

 Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

 NetworkNewsWireAustin, Texaswww.NetworkNewsWire.com512.354.7000 OfficeEditor@NetworkNewsWire.com

 NetworkNewsWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/nnw/networknewsbreaks-oncotelic-therapeutics-inc-otcqb-otlc-featured-in-networknewswire-editorial-on-nanomedicine-advances/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/oncotelic-s-nanotech-platform-revolutionizes-cancer-drug-delivery/1e66b2dd4717a2bf0e0e67cbcd5b6c9b) 

 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/2510/30/odorGOKP.webp)